Skip to main content

Requirements for Batch Production Records

BayBiotech.NET
Batch Production Record is an example of a GMP document and is designed to standardize the process and provides with lot-specific information.
GMP Requirements for Batch Records are defined under following FDA regulations:
 Master Batch Record 21 CFR 211.188
 21 CFR 211.194—Laboratory Records
 21 CFR 211.194—Review by the Quality Control Unit
A batch production record must be established every time a batch is manufactured and must include the following:
Requirements for Laboratory Operations

•Establish and follow written procedures for laboratory operations
•Use adequate laboratory facilities
•Requirements for Laboratory control processes
•Methods for testing and examination
Requirements for Manufacturing Operations
•Establish and follow written procedures for manufacturing operations
•Ensure product specifications are consistent
•Adequate sanitation principles
•Prevent contamination
•Appropriate disposition of rejected or unsuitable dietary supplements
•Requirements for repackaging and relabeling
•Packaged and labeled supplements rejected for distribution
•Record Keeping
•Establish and follow written procedures for holding and distributing operations
•Requirements to hold components, supplements, packaging and labels
•Requirements for in-process materials
•Requirements for reserve samples
•Distribution requirements to protect against contamination and deterioration

The content produced here are part of the QA/Regulatory training taken from Kriger Research Center.

Comments

Popular posts from this blog

FDA Launches Medical Device and Radiation-Emitting Product Transparency Web Site

BayBiotech.NET On April 19th, 2010 FDA launched he Center for Devices and Radiological Health (CDRH) Transparency Web site in support of the agency’s Transparency Initiative. The Web site makes available new information about CDRH’s decision-making processes and displays this information in a more user-friendly format. The site includes new information such as basic information about medical devices and how FDA regulates those products, information about medical devices before and after the products are on the market, in a searchable database, information about the clinical studies and trials conducted to demonstrate the safety and effectiveness of certain medical devices, memos from FDA employees explaining the reasons for the agency's decisions about medical device manufacturer requests to make a significant change in components, materials, design, specification, software, color additive, and labeling of a medical device as well as a step-by-step guide for manufacturers of...

eCTD Submission Specifications

BayBiotech.NET The electronic Common Technical Document (eCTD) is an interface for the pharmaceutical industry to agency transfer of regulatory information. eCTD technical document format development was done by International Conference on Harmonization (ICH) Multidisciplinary Group 2 Expert Working Group (ICH M2 EWG). Details on the specification for the ICH eCTD can be found in the guidance document M2 eCTD: Electronic Common Technical Document Specification. Currently, eCTD is the preferred format for electronic submissions by U.S. Food and Drug Administration. Although originally the CTD and the eCTD were designed for marketing applications, they could apply equally to other submission types, including INDs, master files, advertising material, and promotional labeling. In June 2008, FDA has issued guidelines for organizing the electronic regulatory document filing using the eCTD tools. This guidance discusses issues related to the electronic submission of applications for hum...

Harmonization by Doing (HBD): Japan & U.S. Collaboration

BayBiotech.NET HBD is an international cooperative effort by Japan and US for regulatory convergence for Medical Devices. The efforts are focused on to develop global clinical trials and address regulatory barriers for timely device approvals. To address the needs for additional evaluation, the HBD initiative is a pilot project launched jointly by FDA and MHLW-PMDA for the premarket review of device cardiovascular technology. Instead of taking a theoretical approach to harmonization, HBD is focused on Proof of concept by utilizing parallel development, application submissions and review of actual medical device projects. HBD Study intends to collect and analyze regulatory submission data from multiple applications in the U.S. and Japan. The purpose of the study is to further understand differences that may exist with format and content, to define best practices and to improve globally harmonized processes. To read more about the HBD program, follow the link: http://www.fda.gov/M...